Anavo Therapeutics
PrivateLast Round
Seed
May 2, 2023
Total Funding Raised
$33.34M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Anavo Therapeutics operates in Healthcare & Life Sciences and is based in Leiden. Its latest recorded funding round was a Seed round in May 2023.
Anavo Therapeutics is a biotechnology company that develops phosphatase-based drug discovery platforms to address previously undruggable targets in oncology and other complex diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Anavo Therapeutics Comparables
Compare Anavo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Exo Therapeutics | 79% | |
| Ambagon Therapeutics | 79% | |
| HotSpot Therapeutics | 78% |
For institutional investors. Book with your work email.
Anavo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 2, 2023 | ||||
| Seed | Apr 22, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Anavo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Taiho Ventures | Seed |
| M Ventures | Seed |
| Bioqube Ventures | Seed |
| Inkef Capital | Seed |
| M Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 58% MoM.
- Jun 19, 2026
Monthly visitors increased 59% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 22, 2026
Anavo Tx appoints Vincent G. Brichard, M.D., Ph.D., as Chairman of its Board of Directors in the Netherlands on Sep 22nd '26, as it advances three potentially first-in-class phosphatase programs.
For institutional investors. Book with your work email.
Anavo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Anavo Therapeutics's valuation, stock price, and market status.
Is Anavo Therapeutics a public or private company?
Anavo Therapeutics is a private company.
What is the current stock price of Anavo Therapeutics?
Anavo Therapeutics is a private company, so its shares have no public market price. Caplight tracks Anavo Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Anavo Therapeutics worth (valuation)?
Valuation information for Anavo Therapeutics is not publicly available.
Can I buy Anavo Therapeutics stock?
Anavo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Anavo Therapeutics's last funding round?
Anavo Therapeutics's most recent funding round was Seed on May 2, 2023.
Who are the main investors in Anavo Therapeutics?
Key investors in Anavo Therapeutics include M Ventures, Inkef Capital, M Ventures.
Will Anavo Therapeutics IPO soon?
No public IPO plans have been announced for Anavo Therapeutics.
How can I track Anavo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Anavo Therapeutics's shares on secondary markets.